Trial reportJAMA ophthalmology2013
Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial.
Trial report in JAMA ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review.Diabetes & vascular disease researchPooled it
- The Diabetes Visual Function Supplement Study (DiVFuSS).The British journal of ophthalmology · 2016Trial
- Soluble tumor necrosis factor receptors in diabetes: risk sensing and receptor-resolved targeting.Endocrine journal · 2026Review
- Higher diabetes genetic load in proliferative diabetic retinopathy in South India: The South Indian GeNetics of DiAbeTic Retinopathy (SIGNATR) study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Association of serum proinflammatory factors with clinical response to ranibizumab for diabetic macular edema.Experimental and therapeutic medicine · 2025Article
- High-Sensitivity C-Reactive Protein and its Association with Diabetic Retinopathy: A Cross-sectional Study.Archives of Iranian medicine · 2025Article
- Liquid Biopsy Combined with Multi-Omics Approaches in Diagnosis, Management, and Progression of Diabetic Retinopathy.Biomedicines · 2025Review
- Article
- Review
- Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study.Scientific reports · 2023Article
- Neuroendocrine System Adaptation during Consecutive Extrinsic Stimuli: A Pilot Dynamic Study.Children (Basel, Switzerland) · 2023Article
- Diabetic Retinopathy: Soluble and Imaging Ocular Biomarkers.Journal of clinical medicine · 2023Review
- Identification of miRNA-mRNA Regulatory Networks Associated with Diabetic Retinopathy using Bioinformatics Analysis.Endocrine, metabolic & immune disorders drug targets · 2023Article
- Certain Dietary Nutrients Reduce the Risk of Eye Affliction/Retinopathy in Individuals with Diabetes: National Health and Nutrition Examination Survey, 2003-2018.International journal of environmental research and public health · 2022Article
- Diabetes mellitus associated neurovascular lesions in the retina and brain: A review.Frontiers in ophthalmology · 2022Review
- Correlation between Imaging Morphological Findings and Laboratory Biomarkers in Patients with Diabetic Macular Edema.Journal of diabetes research · 2021Observational
- Relationship between plasma growth differentiation factor-15 levels and diabetic retinopathy in individuals with type 2 diabetes.Scientific reports · 2020Article
- Children with type 1 diabetes have elevated high-sensitivity C-reactive protein compared with a control group.BMJ open diabetes research & care · 2020Article
- The trajectory of high sensitivity C-reactive protein is associated with incident diabetes in Chinese adults.Nutrition & metabolism · 2020Article
- The Optimal Cutoff Value of Neutrophil/Lymphocyte Ratio for Severe Grades of Diabetic Retinopathy.Beyoglu eye journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 2 countries.
Funding
Abstract
importanceThis study demonstrates that increasing quintiles of baseline high-sensitivity C-reactive protein (hsCRP) level may be associated with higher risk of incident clinically significant macular edema, the leading cause of vision loss in working-aged individuals in North America.
objectiveTo determine whether baseline levels of hsCRP and intercellular adhesion molecule 1 (ICAM-1) predict development and progression of diabetic retinopathy (DR), clinically significant macular edema (CSME), retinal hard exudates, and proliferative DR in the Diabetes Control and Complications Trial (DCCT) cohort.
designThe DCCT was a large multicenter randomized controlled clinical trial.
settingTwenty-nine medical centers in the United States and Canada.
participantsThe DCCT population consisted of 1441 subjects with type 1 diabetes mellitus aged 13 to 39 years at study entry.
interventionWe measured levels of hsCRP, ICAM-1, vascular cell adhesion molecule 1, and tumor necrosis factor α receptor 1 in stored baseline blood samples.
main outcome measuresWe assessed the association of levels of hsCRP, ICAM-1, vascular cell adhesion molecule 1, and tumor necrosis factor α receptor 1 with incident DR end points ascertained from grading of standardized 7-field stereoscopic retinal color photographs taken at baseline and every 6 months during follow-up.
resultsAfter adjustment for randomized treatment assignment and other factors, we observed a statistically significant association between hsCRP and risk of CSME, with a relative risk (RR) for the top vs bottom quintile of 1.83 (95% CI, 0.94-3.55; P for trend = .01). Similarly, for the development of retinal hard exudates, the RR for the top vs bottom quintile of hsCRP level was 1.78 (95% CI, 0.98-3.25; P for trend = .004), whereas for ICAM-1 level, the RR comparing the top vs bottom quintiles was 1.50 (95% CI, 0.84-2.68; P for trend = .05). There were no statistically significant associations between baseline VCAM-1 or tumor necrosis factor α receptor 1 levels and risk of any of the DR end points. CONCLUSIONS AND RELEVANCE: After adjusting for known risk factors, increasing quintiles of baseline hsCRP level may be associated with higher risk of incident CSME and macular hard exudate in the DCCT cohort. Circulating levels of ICAM-1 may also be associated with the development of retinal hard exudates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.